|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500107336 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-08 15:44:39 |
|
注册时间: Date of Registration: |
2025-08-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国急诊医学科脓毒症前瞻性研究 |
|
Public title: |
Prospective Study on Sepsis in Emergency Medicine in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国急诊医学科脓毒症前瞻性研究 |
|
Scientific title: |
Prospective Study on Sepsis in Emergency Medicine in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吕传柱 |
研究负责人: |
吕传柱 |
|
Applicant: |
Chuanzhu Lv |
Study leader: |
Chuanzhu Lv |
|
申请注册联系人电话: Applicant telephone: |
+86 177 8983 0771 |
研究负责人电话:
Study leader's |
+86 177 8983 0771 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liquan565@163.com |
研究负责人电子邮件: Study leader's E-mail: |
luchuanzhu@emss.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省成都市青羊区一环路西二段32号 |
研究负责人通讯地址: |
四川省成都市青羊区一环路西二段32号 |
|
Applicant address: |
No. 32, Section 2, West Yihuan Road, Qingyang District, Chengdu City, Sichuan Province, China |
Study leader's address: |
No. 32, Section 2, West Yihuan Road, Qingyang District, Chengdu City, Sichuan Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
四川省人民医院 |
||
|
Applicant's institution: |
Sichuan Provincial People's Hospital |
||
|
研究负责人所在单位: |
四川省人民医院 |
||
|
Affiliation of the Leader: |
Sichuan Provincial People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审(研)2025年第379号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
四川省医学科学院?四川省人民医院基础及临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Basic and Clinical Research Ethics Committee of Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-05-27 00:00:00 | ||
|
伦理委员会联系人: |
姜梅玲 |
||
|
Contact Name of the ethic committee: |
Jiang MeiLing |
||
|
伦理委员会联系地址: |
四川省成都市青羊区一环路西二段32号 |
||
|
Contact Address of the ethic committee: |
No. 32, Section 2, West Yihuan Road, Qingyang District, Chengdu City, Sichuan Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 87393449 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
jiangmeiling1215@163.com |
|
研究实施负责(组长)单位: |
四川省人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Sichuan Provincial People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省成都市青羊区一环路西二段32号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 32, Section 2, West Yihuan Road, Qingyang District, Chengdu City, Sichuan Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
科学技术文献出版社有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Science and Technology Literature |
||||||||||||||||||||||
|
研究疾病: |
脓毒症 |
||||||||||||||||||||||
|
Target disease: |
sepsis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.探索中国综合医院急诊科脓毒症患者的救治策略,并分析影响患者预后的因素。2. 评估不同脓毒症患者亚型和急诊科早期液体复苏策略对患者预后的影响。 3.提供脓毒症早期评估工具,并为脓毒症救治指南提供临床循证依据,尤其是在中国卫生院和120救护车上的应用。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Explore the treatment strategies for sepsis patients in the emergency departments of general hospitals in China and analyze the factors influencing patient outcomes. 2. Evaluate the impact of different sepsis patient subtypes and early fluid resuscitation strategies in the emergency department on patient prognosis. 3. Provide early assessment tools for sepsis and offer clinical evidence-based support for sepsis treatment guidelines, particularly in their application within Chinese community health centers and 120 ambulance services. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄≥18周岁 (2)临床拟诊断为脓毒症或者脓毒症休克(qSOFA≥ 2分+疑似或确诊感染,伴或不伴低血压或血乳酸﹥2mmol/L) |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 18 years old; 2. Clinical diagnosis of sepsis or septic shock (qSOFA >= 2 points + suspected or confirmed infection, with or without hypotension or blood lactate > 2 mmol/L); |
||||||||||||||||||||||
|
排除标准: |
1. 合并急性冠脉综合征、脑卒中、严重创伤、孕产妇等; (2) 年龄﹤18周岁 (3) 充血性心力衰竭急性加重期 (4)其它非脓毒症急症引起的血容量丢失,如糖尿病酮症酸中毒、大量呕吐或腹泻、重度中暑、高渗性昏迷等。 (5)肺水肿或者液体过负荷状态 (6)放弃治疗者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with acute coronary syndrome, stroke, severe trauma, or pregnant/postpartum women; 2. Age < 18 years old ; 3. Acute exacerbation of congestive heart failure ; 4. Non-sepsis-related conditions causing significant volume loss, such as diabetic ketoacidosis, severe vomiting/diarrhea, heat stroke, or hyperosmolar coma ; 5. Pulmonary edema or fluid overload; 6. Patients who have opted to discontinue treatment; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-01 00:00:00至 To 2028-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-01 00:00:00 至 To 2028-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签,对评估者隐藏分组 |
|
Blinding: |
Open-label study with blinded-evaluators |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no sharing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究的临床数据采集与管理采用双轨制系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data collection and management system consists of two components: (1) Case Report Forms (CRFs), and (2) an Electronic Data Capture (EDC) system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |